Biologics Safety Testing Market Size, Share, Regional Growth, 2026-2034
- jhon smith
- May 6
- 4 min read
Market OverviewAccording to fortune business insights, the global biologics safety testing market size was valued at USD 5.90 billion in 2024. The market is projected to grow from USD 6.40 billion in 2025 to USD 11.50 billion by 2032, exhibiting a CAGR of 8.73% during the forecast period. North America dominated the global biologics safety testing market with a market share of 37.97% in 2024.
The analysis shows that the production of biologics and biosimilars is increasing exponentially to address the rising burden of diseases. This surge in production is driving greater adoption of biologics safety testing services and consumables as a critical step in ensuring product quality and patient safety. This trend indicates a strong and growing demand for biologics safety testing worldwide.
Major Players Profiled in the Market Report:
Merck KGaA (Germany)
SGS Société Générale de Surveillance SA (Switzerland)
Thermo Fisher Scientific Inc. (U.S.)
BD (U.S.)
Sartorius AG (Germany)
Charles River Laboratories (U.S.)
Eurofins Scientific (Luxembourg)
Lonza (Switzerland)
Waters Corporation (U.S.)
Reading Scientific Services Ltd (U.S.)
Abzena (U.S.)
Segments
Escalating Adoption of Cell and Gene Therapy to Propel Services Segment GrowthBased on products & services, the market is divided into kits & reagents, instruments, and services. The services segment holds the largest market share and dominates the market owing to the rising adoption of complex cell and gene therapies and a growing trend of outsourcing specialized safety testing to expert providers.
Strong Demand for Viral Safety Tests to Drive Viral Safety/Adventitious Agents Segment ExpansionBy test type, the market is categorized into sterility, endotoxin/pyrogen, mycoplasma, bioburden, viral safety/adventitious agents, residual HCP/HCDNA, cell line characterization, and others. The viral safety/adventitious agents segment is leading the market as this testing is a critical and mandatory component at every stage of biologics manufacturing to ensure products are free from viral contaminants.
Considerable Demand for Monoclonal Antibodies to Dominate the MarketBased on application, the market is segmented into monoclonal antibodies (mAbs) & recombinant proteins, vaccines, cell & gene therapies, blood & plasma products, and tissue/stem cell products. The mAbs & recombinant proteins segment holds the largest market share owing to the extensive research and development pipeline for these therapeutics, which requires rigorous and comprehensive safety testing.
Increasing Bioprocessing Activities to Lead Pharmaceutical & Biotechnology Companies Segment GrowthBased on end-user, the market is split into pharma & biotech companies, CROs/CDMOs, academic & research institutes, and government/regulatory labs. The pharma & biotech companies segment leads market growth as they are the primary developers and manufacturers of biologics, conducting intensive in-house quality checks and driving high-volume adoption of safety testing consumables.
Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Report CoverageThe report offers:
Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
Comprehensive insights into regional developments.
List of major industry players.
Key strategies adopted by the market players.
The latest industry developments include product launches, partnerships, mergers, and acquisitions.
Drivers & Restraints
Exponential Growth of Biologics to Propel Market GrowthThe rapid growth in advanced biologics, particularly cell and gene therapies, has raised the demand for rigorous and frequent safety testing. The complex manufacturing processes for these next-generation modalities carry high contamination risks, making stringent safety protocols at every production stage essential and boosting market growth.
However, the limited availability of high-end infrastructure, such as BSL-2/BSL-3 laboratories, and a shortage of specialized talent can increase operational costs and lead times. These infrastructure and talent constraints may slow adoption and hamper market growth.
Regional Insights
Expanding Pipeline of Biologics Propels Market Growth in North AmericaNorth America holds the dominant biologics safety testing market share and is projected to experience strong growth. The region’s growth is attributed to the presence of a large number of pharmaceutical companies, an expanding pipeline of biologics and cell and gene therapies, and significant investment in R&D for innovative therapies.
Europe is the second-largest region in the market. The growth is attributed to the rise of advanced therapies across the region and the expansion of biosafety testing capabilities by key players to meet increasing regulatory and production demands.
Biologics Safety Testing Market Future Growth:The biologics safety testing market is experiencing robust growth, fueled by a significant shift toward animal-free testing methods. Today's manufacturers are increasingly adopting Rapid Microbiological Methods (RMM) and animal-free endotoxin assays, such as those using Recombinant Factor C (rFC), to meet ethical standards and improve sustainability. These advanced technologies not only reduce reliance on animal-derived components but also shorten batch-release cycles and improve testing consistency, cementing them as a key driver of future market expansion.
Competitive Landscape
Strategic Collaborations and Capacity Expansions to Propel Market GrowthThe market features prominent players like Merck KGaA, SGS Société Générale de Surveillance SA, and Thermo Fisher Scientific Inc. These leading companies are accelerating growth through strategic initiatives such as capacity expansions, new product launches, and collaborations to strengthen their market positions and meet the growing demand for advanced testing services. Their proactive approach to technological advancement and geographic expansion continues to fuel the market’s momentum.
Key Industry Development
October 2025: Charles River Laboratories International, Inc. collaborated with Toxys to gain access to ReproTracker, an in vitro assay that identifies developmental toxicity hazards in new drugs.
September 2025: Bionique Testing Laboratories LLC (Bionique), a subsidiary of Asahi Kasei, expanded its facility to meet the growing demand for rapid biosafety testing solutions.
July 2025: Creative Diagnostics launched its Mammalian HCP ELISA Kits, providing sensitive and reliable detection of Host Cell Proteins (HCPs) in biopharmaceutical manufacturing.
Comments